shortagewatch

Home / Cancer and immune system / Mirikizumab

ATC L04AC24 · Interleukin Inhibitors

Mirikizumab shortage

As of 2 Nov 2026, Mirikizumab has a reported shortage in 1 of the 16 countries we track (United States), covering 2 products from 1 company.

Countries1/16
Products2packs or presentations
Companies11 listed
Short since22 Dec 202510 months ago
Earliest returnnot givencompany estimate
Main reasonNot stated
United States2 products shortCanadaNo reported shortageGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageNew ZealandNo reported shortageAustraliaNo reported shortage

Timeline

United States
2026Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)today

Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.

Which companies are short

products short, all countries
Eli Lilly2 LLY

Listed: Eli Lilly LLY · NYSE

Compared with similar medicines

ATC group L04AC · Interleukin Inhibitors
Tocilizumab5/16Ustekinumab4/16Basiliximab2/16Secukinumab2/16Spesolimab2/16Daclizumab1/16Mirikizumab1/16Risankizumab1/16

Affected products

CountryProductCompanySinceExpected backReason
USOmvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27) discontinuationEli Lilly and Co.22 Dec 2025not givenNot stated
USOmvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27) discontinuationEli Lilly and Co.22 Dec 2025not givenNot stated

"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.